Chronic myeloid leukaemia - standardization of BCR-ABL1 transcript level monitoring in the Czech Republic
2016
Abstract
Molecular monitoring of patients with chronic myeloid leukaemia has become a crucial part of therapeutic practice in the era of tyrosine kinase inhibitors. Introduction of BCR-ABL1 transcript quantification requires harmonization across laboratories worldwide.
A network of BCR-ABL1 laboratories, that regularly undergo standardization and annual external quality controls, has been created in the Czech Republic since 2007. The progressive introduction of European LeukemiaNet recommendations for the management of CML and its molecular monitoring has increased in the increased reliability of BCR-ABL1 transcript level monitoring used for therapeutic decision making as well as the comparability of results from different laboratories.